• 首页
  • 关于期刊
    期刊简介
    编委会
    青年编委会
    合作单位
    《药学研究》编辑部
  • 投稿指南
  • 制度与声明
    出版伦理规范
    学术不端声明
    开放获取(OA)声明
    AIGC工具使用声明
  • 期刊订阅
  • 下载中心
  • English
引用本文:刘春雨,赵云,廖永红,杨飞飞.提高原人参二醇口服生物利用度的固体分散体及其片剂的制备与评价[J].药学研究,2022,41(10):659-663[点击复制]
【打印本页】      【下载PDF全文】   【查看/发表评论】  【下载PDF阅读器】  【关闭】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 2422次   下载 2250次 本文二维码信息
码上扫一扫!
提高原人参二醇口服生物利用度的固体分散体及其片剂的制备与评价
刘春雨,赵云,廖永红,杨飞飞
字体:加大+|默认|缩小-
(中国医学科学院北京协和医学院药用植物研究所,北京 100193)
摘要:
目的 本文拟研究一种加水复溶后可转化为纳米混悬液的新型固体分散体片剂,提高原人参二醇(PPD)口服给药的溶解度和生物利用度。方法 通过将药物、聚合物载体和表面活性剂按10:14:6的比例溶解于乙醇后,减压真空干燥制备固体分散体,然后将固体分散体、乳糖、交联聚乙烯吡咯烷酮和硬脂酸镁按300:16:60:4的比例混合后,直接压成片重400 mg的片剂。结果 发现含泊洛沙姆188和维生素E聚乙二醇琥珀酸酯(TPGS)的原人参二醇固体分散体加水复溶后可转变为纳米混悬液。以乙烯基吡咯烷酮/醋酸乙烯共聚物64(PVP-VA)为载体,维生素E聚乙二醇琥珀酸酯为表面活性剂的固体分散体加水复溶后可转变为平均粒径小于120 nm的纳米混悬液,该混悬液放置8 h后粒径基本稳定。固体分散体经压制成片剂后可在15 min内溶出超过90%的药物,且其溶出的药物可稳定维持至少8 h。固体分散体经大鼠灌胃给药后,其最高血药浓度和生物利用度是原型药物及辅料物理混合物的6.59倍和2.54倍。结论 该研究表明可转化为纳米混悬液的固体分散体片剂是一种可提高原人参二醇口服生物利用度的新制剂方法。
关键词:  原人参二醇  固体分散体  纳米混悬液  维生素E聚乙二醇琥珀酸酯  生物利用度
DOI:10.13506/j.cnki.jpr.2022.10.006
基金项目:国家自然科学基金项目(No.82173983)
Preparation and evaluation of protopanaxadiol solid dispersions tablets for improving oral bioavailability
LIU Chunyu,ZHAO Yu,LIAO Yonghong,YANG Feifei
(Institute of Medicinal Plant Development (IMPLAD), Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100193, China)
Abstract:
Objective This work intended to report a novel solid dispersion tablet enabling to convert to nanosuspensions for improving the dissolution and oral bioavailability of protopanaxadiol (PPD). Methods After dissolving PPD, a polymer and a surfactant with a mass ratio of 10:14:6 in ethanol, the solid dispersion was prepared by vacuum drying of the solution. Subsequently, the solid dispersion powders were compressed to tablets, each of which consisted of solid dispersion powders (300 mg), lactose (16 mg), polyvinylpolypyrrolidone (60 mg) and magnesium stearate (4 mg). Results The results showed that the PPD solid dispersion was converted to a nanosupension upon reconstitution in water. After reconstitution of the solid dispersion consisting of poly(vinyl pyrrolidone-co-vinyl acetate) (PVP/VA) and D-α-tocopherol polyethylene glycol 1000 succinate (TPGS), the nanosuspension with a mean particle size less than 120 nm was obtained and the particle size remained stable for up to 8 h storage. In vitro dissolution data showed that more than 90% of drug in solid dispersion tablets was dissolved within 15 min, markedly higher than ~ 11% of dissolution in the physical mixture tablets of raw PPD material. The drug dissolution state of solid dispersion tablets could maintain at least 8 h. Comparative pharmacokinetic study between solid dispersion and physical mixture tablets was investigated after oral administration to rats. Compared to physical mixture tablets, the maximum plasma concentration and bioavailability of PPD increased by 6.59-fold and 2.54-fold for solid dispersion tablets, respectively. Conclusion The solid dispersion tablets convertible to nanosuspensions represent as a novel formulation means to improve the dissolution and bioavailability of PPD.
Key words:  Protopanaxadiol  Solid dispersion  Nanosuspension  D-α-Tocopherol polyethylene glycol 1000 succinate  Bioavailability
今日访问量:2644    总访问量:55339159
网站版权:《药学研究》编辑部     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
主办:山东省食品药品检验研究院、山东省药学会 地址:山东省济南市高新区新泺大街2749号 邮政编码:250101
电话:0531-81216586 电子邮箱:yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
技术支持:北京勤云科技有限公司